open access

Vol 5, No 6 (2004): Practical Diabetology
Original articles (submitted)
Published online: 2005-02-02
Get Citation

Continuous subcutaneous insulin infusion in preschool children with type 1 diabetes mellitus

Joanna Nazim, Marta Ciechanowska, Aleksandra Górska, Jerzy Starzyk
Diabetologia Praktyczna 2004;5(6):307-310.

open access

Vol 5, No 6 (2004): Practical Diabetology
Original articles (submitted)
Published online: 2005-02-02

Abstract

INTRODUCTION. Continuous subcutaneous insulin infusion (CSII) has been shown to be a safe and effective method of insulin therapy in adults, adolescents and older children with type 1 diabetes mellitus. The aim of this study was to evaluate the results of CSII treatment in preschool diabetic children attending diabetes clinic in University Children Hospital in Kraków.
MATERIAL AND METHODS. The data of 15 children (8 girls, 7 boys) were analysed, mean age at CSII initiation: 5.6 ± 1.6 years (range 2.1–7.8 years), diabetes duration: 2.3 ± 1.1 years (range: 0.8–3.9 years), median follow-up period: 27 months (19–32 months). Glycosylated haemoglobin (HbA1c) was measured at least 4 times a year by HPLC (BioRad).
RESULTS. Mean HbA1c in the year preceeding CSII initiation was 7.1 ± 0.8% and significantly decreased during the first 6 months of CSII treatment to 6.8 ± 0.7% (p < 0.05). HbA1c did not change at the further follow-up 6.7 ± 0.6% after 24 months and 6.8 ± 0.9% after 30 months in 8 kids with the longest period of CSII treatment. Mean HbA1c for all postpump visits for all children was 6.8 ± 0.7%. BMI values did not change (BMI-SDS prepump 0.77 vs. 0.63 during CSII). The total daily insulin requirement decreased from 0.75 U/kg at multiple daily injecions to 0.69 U/kg during pump therapy. The frequency of severe hypoglycemia was the same.
CONCLUSION. CSII is safe and effective method to improve metabolic control in youngest children with type 1 diabetes.

Abstract

INTRODUCTION. Continuous subcutaneous insulin infusion (CSII) has been shown to be a safe and effective method of insulin therapy in adults, adolescents and older children with type 1 diabetes mellitus. The aim of this study was to evaluate the results of CSII treatment in preschool diabetic children attending diabetes clinic in University Children Hospital in Kraków.
MATERIAL AND METHODS. The data of 15 children (8 girls, 7 boys) were analysed, mean age at CSII initiation: 5.6 ± 1.6 years (range 2.1–7.8 years), diabetes duration: 2.3 ± 1.1 years (range: 0.8–3.9 years), median follow-up period: 27 months (19–32 months). Glycosylated haemoglobin (HbA1c) was measured at least 4 times a year by HPLC (BioRad).
RESULTS. Mean HbA1c in the year preceeding CSII initiation was 7.1 ± 0.8% and significantly decreased during the first 6 months of CSII treatment to 6.8 ± 0.7% (p < 0.05). HbA1c did not change at the further follow-up 6.7 ± 0.6% after 24 months and 6.8 ± 0.9% after 30 months in 8 kids with the longest period of CSII treatment. Mean HbA1c for all postpump visits for all children was 6.8 ± 0.7%. BMI values did not change (BMI-SDS prepump 0.77 vs. 0.63 during CSII). The total daily insulin requirement decreased from 0.75 U/kg at multiple daily injecions to 0.69 U/kg during pump therapy. The frequency of severe hypoglycemia was the same.
CONCLUSION. CSII is safe and effective method to improve metabolic control in youngest children with type 1 diabetes.
Get Citation

Keywords

continuous subcutaneous insulin infusion; insulin pump therapy; children; type 1 diabetes

About this article
Title

Continuous subcutaneous insulin infusion in preschool children with type 1 diabetes mellitus

Journal

Clinical Diabetology

Issue

Vol 5, No 6 (2004): Practical Diabetology

Pages

307-310

Published online

2005-02-02

Bibliographic record

Diabetologia Praktyczna 2004;5(6):307-310.

Keywords

continuous subcutaneous insulin infusion
insulin pump therapy
children
type 1 diabetes

Authors

Joanna Nazim
Marta Ciechanowska
Aleksandra Górska
Jerzy Starzyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl